Table 2 Univariate and multifactorial analysis of OS in newly diagnosed MM patients.

From: Progression of disease within 24 months (POD24) in multiple myeloma implicates poor prognosis and limitations of current prediction models for POD24

Clinical character

Univariate Analysis

Multivariate Analysis

HR(95%CI)

P value

HR(95%CI)

P value

Age(>60)

1.898(1.455–2.477)

0.000

1.300(0.982–1.722)

0.067

Hemoglobin(< 100 g/L)

1.680(1.264–2.233)

0.000

1.053(0.763–1.454)

0.754

Lactate dehydrogenase (> 245U/L)

1.605(1.160–2.219)

0.004

1.447(1.033–2.027)

0.032

β2 -microglobulin (> 3.5 mg/L)

2.456(1.784–3.380)

0.000

1.728(1.203–2.484)

0.003

Creatinine(> 177 µmol/L)

2.231(1.704–2.922)

0.000

1.563(1.152–2.122)

0.004

Blood calcium

(> 2.75 mmol/L)

2.623(1.830–3.760)

0.000

1.576(1.046–2.374)

0.030

POD24

2.100(1.631–2.704)

0.000

1.956(1.507–2.541)

0.000

Treatment (without bortezomib)

0.617(0.480–0.794)

0.000

0.638(0.490–0.831)

0.001

Chromosomal abnormality

1.248(0.940–1.657)

0.126

  

Non-transplantion

0.111(0.052–0.235)

0.000

0.171(0.079–0.371)

0.000